ResMed Inc. stock: Earnings beat but shares slip on guidance concerns

ResMed Inc. shares fell about 8% this week despite a strong quarterly earnings beat, as investors weigh guidance and valuation.

ResMed Inc. stock slipped roughly 8% this week even as the company reported a solid earnings beat, highlighting investor caution around guidance and valuation in the sleep and respiratory care sector. The pullback comes after ResMed’s third?quarter fiscal 2026 results showed double?digit revenue growth and strong profit expansion, yet the stock now trades near its 52?week low, according to market data compiled by Tikr as of May 08, 2026.

For the quarter ended March 31, 2026, ResMed reported revenue of about $1.43 billion, up 11% year over year, though that figure slightly missed consensus expectations, while adjusted earnings per share of $2.86 beat estimates by about 1.78% and rose 21% versus the prior?year quarter, according to Investing.com as of May 08, 2026. The company highlighted continued strength in its mask and device portfolio, including the AirSense 11 platform, which has helped drive market?share gains in sleep apnea and respiratory care.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ResMed Inc.
• Sector/industry: Healthcare, medical devices
• Headquarters/country: United States
• Core markets: United States, Europe, Asia?Pacific
• Key revenue drivers: Sleep apnea devices, masks, respiratory care products
• Home exchange/listing venue: New York Stock Exchange (ticker: RMD)
• Trading currency: U.S. dollar

ResMed Inc.: core business model

ResMed Inc. designs, manufactures and distributes medical devices and cloud?connected software for the diagnosis, treatment and management of sleep?disordered breathing and other respiratory conditions. The company’s core business revolves around continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories used primarily in home?based sleep apnea therapy, as well as ventilators and respiratory care products for hospital and long?term care settings.

ResMed’s business model combines hardware sales with recurring revenue streams from consumables such as masks, tubing and filters, as well as software and data?driven services that support remote patient monitoring and therapy adherence. This mix of durable equipment and high?margin consumables underpins relatively stable cash flows and recurring demand, which is important for investors seeking exposure to the chronic?disease management segment of the healthcare sector.

Main revenue and product drivers for ResMed Inc.

ResMed’s main revenue drivers are its sleep apnea devices and masks, which together account for the bulk of the company’s sales. The AirSense 11 platform, introduced in prior years, has become a key growth engine, offering advanced algorithms, improved comfort and integrated connectivity that help clinicians and patients track therapy adherence and outcomes. These features have contributed to market?share gains in the global sleep apnea device market, where ResMed competes with a small number of large medical?device peers.

In addition to sleep therapy, ResMed’s respiratory care portfolio includes ventilators and related products used in acute and chronic respiratory conditions, such as chronic obstructive pulmonary disease (COPD) and neuromuscular disorders. The company also generates revenue from cloud?based software platforms that aggregate therapy data and provide analytics for healthcare providers, payers and home?care organizations. This software and services segment is growing as payers increasingly focus on outcomes?based reimbursement and remote monitoring.

Why ResMed Inc. matters for US investors

For US investors, ResMed offers exposure to a high?margin, innovation?driven segment of the healthcare equipment market with strong secular tailwinds from aging demographics, rising obesity rates and greater awareness of sleep apnea. The company is listed on the New York Stock Exchange under the ticker RMD and derives a significant portion of its revenue from the United States, making it a relevant name for portfolios focused on domestic healthcare infrastructure and medical technology.

ResMed’s valuation multiples, including a price?to?earnings ratio around 30 times trailing earnings and a price?to?sales ratio above 8 times, sit above sector averages, according to Investing.com as of May 08, 2026. That premium reflects expectations of continued growth in sleep and respiratory care, but also means the stock is sensitive to any perceived slowdown in demand, pricing pressure or regulatory changes in reimbursement.

Conclusion

ResMed Inc. delivered a strong earnings beat in its third quarter of fiscal 2026, with double?digit revenue growth and double?digit earnings per share growth, yet the stock has retreated toward its 52?week low as investors digest guidance and valuation. The company’s leadership in sleep apnea devices and respiratory care, combined with recurring revenue from consumables and software, provides a solid foundation, but the premium valuation leaves little room for disappointment on future quarters.

US investors considering ResMed should weigh the company’s exposure to long?term demographic and healthcare?spending trends against the risks of regulatory changes, competitive pressures and potential reimbursement shifts in sleep and respiratory therapy. The recent price move underscores that even fundamentally strong companies can experience volatility when expectations are high, and that careful attention to guidance, margins and capital allocation is important for long?term positioning.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.